Zhejiang, China (October, 2017) — China-based, a pharmaceutical process development, Active Pharmaceutical Ingredient (API) and preparation manufacturing company, announced today that its Zhejiang, China OSD manufacturing site has successfully completed a routine U.S. Food and Drug Administration (FDA) inspection.

The cGMP (current Good Manufacturing Practices) Audit was completed over five days, in September, 2017.

The inspection consisted of an analysis of all Quality Systems, processes and procedures related to the development, validation and manufacture of APIs and highly-potent APIs at the site.

 “Under the guidance of Novo Science Consulting team (Alban Group), The successful FDA inspection of our site, proceeded by two successful inspections of our two other sites in China, reinforces our commitment to delivering the highest standard of quality that our customers expect from us” said their CEO. “We look forward to sharing this exciting news with our customers at CPhI in China.”